MEDICINES worth $142 million have been added to the Pharmaceutical Benefits Scheme from 01 Jul 2017, including Zolinza (vorinostat) for patients with cutaneous T-cell lymphoma.
Also being listed is Humira (adalimumab) for the treatment of inflammatory skin disease hidradentis suppurativa.
The expanded PBS includes Esbriet (pirfenidone) for idiopathic pulmonary fibrosis, with the PBS website now featuring the full schedule along with formulary allocations and therapeutic relativity sheets - www.pbs.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Jul 17